High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium

Journal of Pathology: Clinical Research

Volumn 2, Issue 3, 2016, Pages 138-153

  Abubakar, Mustapha ^a   Howat, William J ^b   Daley, Frances ^a   Zabaglo, Lila ^c   McDuffus, Leigh Anne ^b   Blows, Fiona ^b   Coulson, Penny ^a   Raza Ali, H ^b   Benitez, Javier ^d,e   Milne, Roger ^f,g   Brenner, Herman ^h   Stegmaier, Christa ⁱ   Mannermaa, Arto ^j,k   Chang Claude, Jenny ^h,l   Rudolph, Anja ^h   Sinn, Peter ^m   Couch, Fergus J ⁿ   Tollenaar, Rob A E M ^o   Devilee, Peter ^o   Figueroa, Jonine ^p   Sherman, Mark E ^q   Lissowska, Jolanta ^r   Hewitt, Stephen ^q   Eccles, Diana ^s   Hooning, Maartje J ^t   Hollestelle, Antoinette ^t   Martens, John ^t   HM van Deurzen, Carolien ^t   Investigators, kConFab ^u   Bolla, Manjeet K ^b   Wang, Qin ^b   Jones, Michael ^a   Schoemaker, Minouk ^a   Broeks, Annegien ^v   van Leeuwen, Flora E ^v   Van't Veer, Laura ^v   Swerdlow, Anthony J ^a   Orr, Nick ^a   Dowsett, Mitch ^a,c   Easton, Douglas ^b   Schmidt, Marjanka K ^v   Pharoah, Paul D ^b   Garcia Closas, Montserrat ^q   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d Structural Biology and Biocomputing Programme   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ SAARLAND CANCER REGISTRY   (Germany)

^j UNIVERSITY OF EASTERN FINLAND   (Finland)

^k KUOPIO UNIVERSITY HOSPITAL   (Finland)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ MAYO CLINIC   (United States)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF EDINBURGH   (United Kingdom)

^q NATIONAL CANCER INSTITUTE   (United States)

^r INSTITUTE OF ONCOLOGY   (Poland)

^s SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^t ERASMUS MC CANCER INSTITUTE   (Netherlands)

^u QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^v ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

more..

Author keywords

automated algorithm; breast cancer; immunohistochemistry; Ki67; tissue microarrays

Indexed keywords

KI 67 ANTIGEN;

ACCURACY; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; BREAST CANCER; CANCER TISSUE; CORRELATION ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MACHINE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; TISSUE MICROARRAY;

EID: 85056746527     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.42     Document Type: Article

References (56)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797):747–752.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci 2001; 98(19):10869–10874.
3. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7(5):e1000279.
4. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8):1160–1167.
5. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium Studies. J Nat Cancer Institute 2011; 103(3):250–263.
6. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor–defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomark Prevent 2004; 13(10):1558–1568.
7. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24(9):2206–2223.
8. Aebi S, Davidson T, Gruber G, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(suppl 6):vi12–vi24.
9. Sherman ME, Howatt W, Blows FM, et al. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomark Prevent 2010; 19(4):966–972.
10. do Reis FJC, Lynn S, Ali HR, et al. Crowdsourcing the general public for large scale molecular pathology studies in cancer. EBioMedicine 2015; 2(7):679–687.
11. Polley M-YC, Leung SCY, McShane LM, et al. An International Ki67 reproducibility study. J Nat Cancer Institute 2013; 105(24):1897–1906.
12. Mikami Y, Ueno T, Yoshimura K, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci 2013; 104(11):1539–1543.
13. Gudlaugsson E, Skaland I, Janssen EAM, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 2012; 61(6):1134–1144.
14. Bolton KL, Garcia-Closas M, Pfeiffer RM, et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomark Prevent 2010; 19(4):992–999.
15. Faratian D, Kay C, Robson T, et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM trial experience. Histopathology 2009; 55(5):587–593.
16. Turbin D, Leung S, Cheang MU, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 2008; 110(3):417–426. English.
17. Ali HR, Irwin M, Morris L, et al. Astronomical algorithms for automated analysis of tissue protein expression in breast cancer. Br J Cancer 2013; 108(3):602–612.
18. Howat WJ, Blows FM, Provenzano E, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol: Clin Res 2015; 1(1):18–32.
19. Rexhepaj E, Brennan DJ, Holloway P, et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008; 10(5):R89.
20. DiVito KA, Berger AJ, Camp RL, et al. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in Melanoma. Cancer Res 2004; 64(23): 8773–8777.
21. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11(16): 5856–5862.
22. Lee CM, Lee RJ, Hammond E, et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004; 93(1): 209–214.
23. Pinder S, Wencyk P, Sibbering D, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71(1): 146.
24. Pietiläinen T, Lipponen P, Aaltomaa S, et al. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 1996; 122(11): 687–692.
25. Fasanella S, Leonardi E, Cantaloni C, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagnost Pathol 2011; 6(Suppl 1): S7.
26. Konsti J, Lundin M, Joensuu H, et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011; 11(1): 3.
27. Mohammed ZMA, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106(2): 383–388.
28. Klauschen F, Wienert S, Schmitt WD, et al. Standardized Ki67 diagnostics using automated scoring – clinical validation in the GeparTrio Breast Cancer Study. Clin Cancer Res 2015; 21(16): 3651–3657.
29. Tuominen VJ, Ruotoistenmaki S, Viitanen A, et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010; 12(4): R56.
30. BCAC. Breast Cancer Association Consortium [cited 2015 19/08/ 2015]. Available from: http://apps.ccge.medschl.cam.ac.uk/consortia/bcac//index.html.
31. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res 2014; 16 : R35.
32. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Nat Cancer Institute 2011; 103(22): 1656–1664.
33. Stuart-Harris R, Caldas C, Pinder S, et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17(4): 323–334.
34. Cohen J. Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit. Psychol Bull 1968; 70(4): 213.
35. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59(6): 943–947.
36. Barnard NJ, Hall PA, Lemoine NR, et al. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152(4): 287–295.
37. Trihia H, Murray S, Price K, et al. International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker. Cancer 2003; 97(5): 1321–1331.
38. Bottini A, Berruti A, Bersiga A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001; 85(8): 1106–1112.
39. Rudolph P, Olsson H, Bonatz G, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999; 187(2): 207–276.
40. Brown RW, Allred CD, Clark GM, et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996; 2(3): 585–592.
41. Spyratos F, Ferrero-Poüs M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers. Cancer 2002; 94(8): 2151–2159.
42. Moriki T, Takahashi T, Kataoka H, et al. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int 1996; 46(12): 953–961.
43. Pierga JY, Leroyer A, Viehl P, et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996; 37(1): 57–64. English.
44. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine Relat Cancer 2010; 17(4): R245–R262.
45. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23(28): 7212–7220.
46. Reed A, Kutasovic J, Lakhani S, et al. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res 2015; 17(1): 12. doi:10.1186/s13058-015-0519-x.
47. Krüger S, Fahrenkrog T, Müller H. Proliferative and apoptotic activity in lobular breast carcinoma. Int J Mol Med 1999; 4(2): 171–174.
48. Arpino G, Bardou V, Clark G, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004; 6(3): R149–R156.
49. Gasparini G, Pozza F, Meli S, et al. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res 1991; 11(6): 2015–2021.
50. Gasparini G, Bevilacqua P, Pozza F, et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 1992; 66(5): 970–976.
51. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Europ J Cancer 1993; 29(7): 1018–1023.
52. Ioachim E, Kamina S, Athanassiadou S, et al. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 1996; 16(5B): 3141–3147.
53. Liu S, Edgerton SM, Moore DH, et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001; 7(6): 1716–1723.
54. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997; 74(4): 433–437.
55. Wintzer HO, Zipfel I, Schulte-Mönting J, et al. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67(2): 421–428.
56. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Method 2012; 9(7): 671–675.